Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.

@article{Shaw2013PemetrexedbasedCI,
  title={Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.},
  author={Alice Tsang Shaw and Anna M. Varghese and Benjamin J. Solomon and D B Costa and Silvia Novello and Mari Mino-Kenudson and Mark M. Awad and Jeff A. Engelman and Greg J Riely and Valentina Monica and Beow Yong Yeap and Giorgio V Scagliotti},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2013},
  volume={24 1},
  pages={59-66}
}
BACKGROUND Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib. To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS) of ALK-positive versus ALK-negative patients who had been treated with pemetrexed-based chemotherapy for advanced NSCLC. PATIENTS AND METHODS We identified 121 patients with advanced, ALK-positive NSCLC in the USA, Australia, and Italy… CONTINUE READING